References
- Ahmad F, Khalid P, Khan MM, et al. (1991). Hypoglycemic activity of Pterocarpus marsupium wood. J Ethnopharmacol 35:71–5
- Ahmed AB, Rao AS, Rao MV. (2010). In vitro callus and in vivo leaf extract of Gymnema sylvestre stimulate beta cells regeneration and anti-diabetic activity in Wistar rats. Phytomedicine 17:1033–9
- Drucker DJ. (2003). Glucagon-like peptides: Regulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol 17:161–71
- Inzucchi SE. (2002). Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. J Am Med Assoc 287:360–72
- Kanetkar P, Singhal R, Kamat M. (2007). Gymnema sylvestra: A memoir. J Clin Biochem Nutr 41:77–81
- Kikkawa F, Kajiyama H, Shibata K, et al. (2005). Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751:45–51
- Lindsay JR, Duffy NA, McKillop AM, et al. (2005). Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 22:654–7
- Manish D, Arun N, Ansari SH. (2009). Pterocarpus marsupium Roxb. – A comprehensive review. Phcog Rev 3:359–63
- Manjeshwar SB, Harshith PB, Bantwal RVB, et al. (2011). Phytochemistry, traditional uses and pharmacology of Eugenia jambolana Lam. (black plum): A review. Food Res Int 44:1776–89
- Michel MC, Fliers E, Van Noorden CJ. (2008). Dipeptidyl peptidase IV inhibitors in diabetes: More than inhibition of glucagon-like peptide-1 metabolism? Naunyn Schmiedebergs Arch Pharmacol 377:205–7.
- Ng VWS, Kong APS. (2007). Dipeptidyl peptidase (DPP)-IV inhibitor: A novel class of oral anti-hyperglycemic agents. Drug Rev 12:33–4
- Nigel U, David W, Leonor G, et al. (2011). The IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation
- Perry T, Greig NH. (2002). The glucagon-like peptides: A new genre in therapeutic targets for intervention in Alzheimer’s disease. J Alzheimers Dis 4:487–96
- Ravi K, Rajasekaran S, Subramanian S. (2005). Antihyperlipidemic effect of Eugenia jambolana seed kernel on streptozotocin-induced diabetes in rats. Food Chem Toxicol 43:1433–9
- Rosenstock J, Zinman B. (2007). Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 14:98–107
- Sharma B, Balomajumder C, Roy P. (2008). Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food Chem Toxicol 46:2376–83
- Thomas L, Eckhardt M, Langkopf E, et al. (2008). (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175–82
- Yamazaki K, Yasuda N, Inoue T, et al. (2006). 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 319:1253–7